ABSTRACT
INTRODUCTION
Plasmid-based, nonviral gene delivery systems offer a promising therapeutic approach for the treatment of acquired diseases, infectious diseases and inherited disorders (5, 11, 12, 15) . However, their efficiencies and clinical potencies are limited today by low-level gene product expression (10) . The most commonly explored approach for increasing in vivo plasmid expression is to develop improved delivery systems by mimicking the advantageous aspects of viral systems with simplified components. The key features for such nonviral delivery systems are (i) DNA condensation, (ii) cell surface targeting, (iii) endosomal release, (iv)nuclear uptake and (v) avoidance of nonspecific absorption of the delivery system by nontarget tissues.
The delivery systems under investigation today are designed to dissociate from the plasmid after intracellular delivery because the release of DNA from the carrier is usually considered a requirement for transcription to begin (20, 21, 23) . However, for some purposes such as improved nuclear uptake, better cytoplasmic delivery, cell-specific targeting or DNA immunization, it would be desirable to make permanent, irreversible modifications to the plasmid. Unfortunately, there are no wellestablished methods for making irreversible modifications to plasmid in a manner that does not interfere with its transcriptional activity. The peptide nucleic acid (PNA)-dependent gene chemistry (PDGC) technology described in this report was developed to provide a way to make permanent modifications to plasmids without interfering with their transcriptional activity.
PNA is a polynucleic acid analog that has the deoxyribose-phosphate backbone replaced by a peptide backbone (4, 6, 17) . PNA can hybridize with complementary DNA in a typical Watson/Crick manner except that the affinity of the PNA-DNA hybrid is much stronger than the DNA-DNA hybrid. This is because of the neutral charge of the PNA backbone, which does not introduce a repulsive force to drive the hybridized strands apart (2, 4, 7, 8, 17) . PNA has been shown capable of invading duplex DNA and hybridizing to plasmid to form a stable PNA-DNA-PNA triplex hybrid, while displacing the native complementary DNA strand to form a nonhybridizing D-loop (2, 3) .
We previously reported that fluorescein-or rhodamine-conjugated PNA clamps could be hybridized to supercoiled DNA, which leads to the production of a highly fluorescent plasmid and which could be used to follow the delivery of the DNA in living cells (22) . A PNA clamp is an oligomer that has two identical PNA sequences joined by a flexible hairpin linker (8, 13) . Binding of the PNA clamp to its DNA target is sequence-specific, stoichiometric, extremely stable and essentially irreversible under biological conditions (8, 22) . The use of rhodamine-labeled, plasmid-encoding green fluorescent protein (GFP) provided a dual fluorescent system for rapid, quantitative and simul -taneous monitoring of both plasmid biodistribution and gene expression in real time (22) . In this report, we extend these findings to show that PNA clamps containing either biotin or maleimide can be used to synthesize plasmids containing peptides and oligonucleotides.
MATERIALS AND METHODS

PNA, Oligonucleotide, Plasmid DNA and Peptide
The PNA used for these studies was designed as a clamp as previously reported (8, 22) . PNA-biotin, -SMCC [succinimidyl-4-( N -maleimidomethyl) cyclohexane-1-carboxylate], -rhodamine and -fluorescein were purchased from PE Biosystems (Foster City, CA, USA). The PNA sequences used were (22) . Biotin, SMCC, rhodamine and fluorescein are covalently attached to the PNA at the 5 ′ end. The 3 ′ thiol modified CpG oligonucleotide (CpG ODN; 5 ′ -Fl-TGACT -GTGAACGTTCGAGATGA-(CH 2 ) 3 -S-S-(CH 2 ) 3 -OH-3 ′ ) was purchased from Sigma-Genosys (The Woodlands, TX, USA). The ODN were labeled with fluorescein at their 5 ′ end. Plasmid DNA (Figure 1 ) was derived from a high-expression vector based on the human cytomegalovirus (hCMV) immediate early gene promoter/enhancer plus intron A and a super transcription terminator (pGeneGrip ™; Gene Therapy Systems, San Diego, CA, USA). The pGeneGrip blank or β -galactosidase plasmid containing a single PNA binding site was constructed as reported (22) . For the construction of plasmid containing multiple PNA binding regions, two complementary oligonucleotides were synthesized and annealed to form a 101 bp DNA fragment containing 10 PNA binding sites (16) and a 5 ′ overhang with sequence GATC at the ends for inserting into the BamHI or Bgl II cloning site. The pGeneGrip plasmid containing two binding regions was constructed by inserting the 101 bp fragment into a Bgl II site of the original pGeneGrip vector ( Figure 4A ). The nuclear localization signal peptide from simian virus 40 (SV40) T-antigen homologue was purchased from Sigma (St. Louis, MO, USA).
Preparation of DNA/PNA Conjugates DNA/PNA-biotin-SMCC, -rhodamine or -fluorescein. The PNA clamp was mixed with the plasmid (pDNA, gWIZ ™ vectors; Gene Therapy Systems) as described (16) . After the incubation period, free PNA conjugates were completely removed by ethanol precipitation, and the dried plasmid pellet was resuspended in sterile filtered Hepes-buffered saline (HBS; 10 mmol/L Hepes, 50 mmol/L NaCl, pH 7.2) overnight at 4°C. Plasmid recovery was determined spectrophotometrically at 260 nm. Removal of free PNA was confirmed by Sephacryl-500HR (Amersham Pharmacia Biotech, Piscataway, NJ, USA) gel filtration column.
DNA/PNA-Biotin -Streptavidin-FITC or Streptavidin-Gold. The 10 nm diameter Colloidal Gold-labeled streptavidin or streptavidin-FITC (Sigma) was mixed with biotin-PNA-labeled plasmid at 10:1 molar ratio excess and incubated for 1 h at 37°C. After the incubation, the mixture was passed over a Sephacryl-500-HR column to remove the free streptavidingold or -FITC.
Coupling of NLS Peptide and ODN to Streptavidin-SMCC
First, the nuclear localization signal (NLS) peptide was fluorescently labeled using Alexa ™488 Protein Labeling Kit (Molecular Probes, Eugene, OR, USA). The labeled NLS-peptide was subsequently reduced for 2 h with 10 molar excess of tris-(2-carboxyethyl) phosphine, hydrochloride (TCEP; Molecular Probes). After the peptide reduction, an equal molar amount of streptavidin-SMCC (Sigma), was added to the NLS-peptide and incubated at 37°C water bath for 1 h. The uncoupled peptide was removed by Sephadex G50 column chromatography. Fluorescence of each fraction was measured in a dual scanning fluorometer (FluoroMax-2 ® ; Instruments S.A., Edison, NJ, USA). The Alexa labeled NLS-peptide coupled to streptavidin-SMCC was recovered and used to bind the biotin-PNA-labeled plasmid.
Fluorescent CpG oligonucleotide dissolved in PBS at 2 mg/mL was reduced with 40 mmol/L of dithiothreitol (DTT; Life Technologies, Gaithersburg, MD, USA) for 18 h at room temperature and then purified by Sephadex G-50 (Amersham Pharmacia Biotech) gel filtration column. Absorbance at 260 nm of the collected fraction was determined, and fractions containing the CpG ODN were pooled. The reduced and purified CpG ODN was then mixed with streptavidin-SMCC at 5:1 molar ratio of CpG ODN to streptavidin-SMCC and let stand at room temperature for at least 4 h. The CpG ODNstreptavidin conjugate was subsequently bound to biotin-PNA/DNA and visualized after gel electrophoresis under UV.
Cryo-Atomic Force Microscopy (AFM) (19)
Streptavidin-FITC attached to BamHI linearized pDNA/DNA-biotin sample was concentrated using Centricon-100 ™ (Millipore, Bedford, MA, USA). The PBS buffer was exchanged for TE buffer (10 mmol/L Tris-HCl, 1 mmol/L EDTA, pH 8.0). For AFM, the DNA sample was diluted to 2 µ g/mL, adsorbed to a 5 × 5 mm square cleaved mica wafer (SPI Supplies, West Chester, PA, USA) coated with 1 mmol/L spermidine (Sigma) and let stand at room temperature for 5 min. The mica was then washed extensively with TE buffer and briefly rinsed with deionized water. The sample was dried under nitrogen and then cooled to liquid nitrogen temperature. The scope was operated at 80 K (-190°C). The data was collected in the contact mode at a scanning rate of 1-2 Hz. The images were only flattened and no other manipulation was used.
In-Vitro Transfection and Transmission Electron Microscopy (TEM)
We plated 200 000 COS-1 cells onto Thermanox ™ coverslips (Nalge Nunc International, Rochester, NY, USA) placed inside a 6-well plate, 24 h before transfection. Five micrograms of blank mammalian plasmid DNA vector (gWIZ; Gene Therapy Systems) were used per well. DNA/PNA-biotin-streptavidin-gold was mixed with DMRIE/ DOPE (50:50) as described (16) . The cell transfection was done as previously reported (9) . After 48 h of transfection, the transfected cells were rinsed with 1 × PBS, fixed with 3.3% formaldehyde, 1% glutaraldehyde in PBS and stored at 4°C. The samples were post-fixed in 2% osmium tetroxide in distilled water and dehydrated in an alcohol series. Then, the samples were embedded in EponEMBed 812 (Electron Microscopy Sciences, Fort Washington, PA, USA), trimmed and mounted on a LKB ™ Nova ultramicrotome. Approximately 90 nm thin sections were cut using a Diatome diamond knife (Electron Microscopy Sciences). The sections were picked up on formvar-coated grids. The sections were viewed on a Philips 410 TEM either unstained or stained with uranyl acetate and lead citrate. Finally, the images were captured on Kodak SO-163 film (Eastman Kodak, Rochester, NY, USA).
Coupling of NLS Peptide and ODN to DNA by PNA-SMCC
We reduced 1 mg of NLS-peptide dissolved in 200 µ L of Na phosphate buffer with 5 mmol/L of TCEP for 2 h at room temperature. After reduction, DNA/PNA-SMCC and reduced NLS peptide were mixed at 20 moles of NLS peptide/mole of PNA-SMCC in a coupling reaction buffer (100 mmol/L Na phosphate, 150 mmol/L NaCl, pH 7.2) and incubated at least 4 h at room temperature. The DNA/PNA-SMCC-peptide and the uncoupled peptide were separated by isopropanol precipitation. The dried pellet was dissolved in deionized water and the amount of pDNA recovered was measured by absorbance at 260 nm. Finally, the reaction product was analyzed by agarose gel electrophoresis.
For the coupling of the fluorescent CpG ODN to DNA/PNA-SMCC, the ODN was first reduced as described above. The CpG ODN was then mixed with DNA/PNA-SMCC at 20:1 molar ratio for at least 4 h at room temperature. The DNA/PNA-SMCC-CpG ODN conjugate was subsequently purified by isopropanol purification and visualized by agarose gel electrophoresis.
Gel Electrophoresis Analysis
We analyzed 2 µ g of DNA/PNA or DNA/PNA-peptide or -ODN conjugates on a 0.8% TAE agarose gel and electrophoresed them for 2 h at 82 V. peptide or ODN attached to the DNA/PNA, it is critical to use an ethidium bromide-free gel box. For the direct coupling of the NLS peptide to DNA/PNA-SMCC, the peptide was labeled after coupling by using the ATTO-TAG labeling kit ™ (Molecular Probes). Then, the fluorescence from the peptide or ODN attached to pDNA was visualized and photographed with the UV-transilluminator Model TM-10E (UVP, Upland, CA, USA). After visualization of the fluorescent peptide or ODN, gels were labeled with ethidium bromide to check DNA integrity. The photographs were scanned using a HP ScanJet 2CX/T ™ (Hewlett Packard) before and after staining the gel with ethidium bromide.
RESULTS
Principal of PDGC Technology
PNA-labeled plasmids were prepared as shown in Figure 1 . An 80 bp polypurine AG repeat sequence (PNA Binding Site 1, PNABS1) was cloned after the terminator of a CMV immediate early gene promoter-based plasmid. This region of the plasmid was selected for insertion of the binding site because it is not involved in transcription and PNA binding to this region does not affect expression (22) . A complementary PNA clamp molecule was synthesized consisting of an 8-base CT repeat, a 3-unit flexible linker (8-amino-3, 6, -dioxaoctanoic acid), and an 8-base JT repeat (J is pseudoisocytosine, an analog of C, which encourages formation of the Hoogsteen triplex hybrid) (8, 22) . The CT stretch hybridizes to the AG repeat on the plasmid in an antiparallel Watson-Crick manner and the JT stretch binds in the major groove of the PNA-DNA hybrid by Hoogsteen interactions to form the PNA-DNA-PNA triplex clamp (8) . The nontarget DNA strand is displaced forming the nonhybridized D-loop (2, 3) .
To further illustrate the specificity and selectivity of PNA clamp binding, a second PNA binding site (PNABS2) with the repeating sequence AAGG was cloned into the pGeneGrip plasmid. This site was created on a 101 bp synthetic duplex oligonucleotide with sticky ends, and the oligonucleotide was cloned into a restriction site as shown on the pGeneGrip plasmid map in Figure 2 . A complementary PNA clamp molecule was synthesized consisting of an 8-base CCTT repeat on the Watson-Crick portion of the clamp and an 8-base JJTT repeat on the Hoogsteen portion. The two fluorescently labeled PNA clamps were added to the plasmid, the plasmid was restricted and the fluorescence of the restriction fragments was examined on agarose gels. The results in Figure 2 show that the CT PNA clamp (PNA1) binds only to PNABS1 and the CCTT PNA clamp (PNA2) binds only to PNABS2. In addition to showing the specificity and selectivity of PNA clamp binding, these results illustrate that different molecular species can be specifically attached to the same plasmid by binding different PNA clamps selectively to different sites on the plasmid. We have also shown that the number of PNA binding sites can be systematically increased in plasmids by increasing the number of oligonucleotides cloned into the plasmid. In this way, eight of the 101 bp oligonucleotides were cloned into a single plasmid, resulting in a plasmid that contained 80 potential PNA clamp binding sites (data not shown).
Use of the Biotin-Streptavidin Approach to Attach Ligands to Plasmid DNA
One approach uses the biotin-streptavidin system for coupling peptides, proteins, oligonucleotides or other types of ligands to DNA. Here, a DNA-PNA-biotin hybrid is used to capture streptavidin. A number of straightforward chemical methods are available for covalently attaching peptides and proteins to streptavidin. For example, any ligand that contains a free sulfhydryl group will react with streptavidin that contains a conjugated maleimide moiety. Peptide-streptavidin conjugates can be added directly to biotin-PNA-DNA leading to the generation of a product of the kind shown schematically in Figure 4 .
To demonstrate the feasibility of this approach, we prepared streptavidin-labeled plasmid DNA as shown in the Figure 3A . First, biotin-PNA was added to the plasmid and the unbound biotin-PNA was removed by ethanol precipitation. Streptavidin was added to the biotin-PNA-labeled plasmid, and this product was purified by gel filtration to remove unbound streptavidin. Quantitative analysis of the gel filtration data showed that there was approximately 1 bound streptavidin for every plasmid (data not shown). After streptavidin labeling was carried out as described above and illustrated in Figure 3A , the plasmid that contains a single BamH1 site 310 bp away from the PNA binding site was restricted with the BamH1 enzyme. Cryo-AFM images of the streptavidin-labeled DNA are shown in Figure  3B . The micrographs revealed linearized DNA and a white dot on each strand that showed the location of the streptavidin molecule. Virtually every strand had a single streptavidin positioned precisely 310 bp away from the end of each strand at the predicted location of the PNA binding site.
These results illustrate the exquisite specificity and selectivity of this approach for labeling plasmid DNA. The results in Figure 3C show that streptavidin-gold-labeled plasmid can be produced in this way and that intracellular plasmid can be localized by transmission electron microscopy on transfect - ed cells. Gold-labeled plasmid DNA can be seen in the extracellular space ( Figure 3C , top) and in the cytoplasm ( Figure 3C , top, middle and bottom). It was also observed attached to the cell surface and in endocytotic vesicles ( Figure 3C , middle and bottom). The coupling of peptides or oligonucleotides to plasmid with the PNA-biotin-streptavidin linkage was accomplished by using the heterobifunctional cross-linker SMCC, which reacts with streptavidin to form a stable amide bond, leaving a maleimide moiety accessible for reaction with sulfhydryl groups. The peptide used for these studies was an SV40 NLS peptide containing an N-terminal cysteine residue. To detect the peptide, it was first labeled with the fluorescent succinimidyl Alexa 488 dye that reacts with the primary amino groups (lysine residues) on the peptide. After being reduced with DTT, the fluorescent peptide was reacted with streptavidin-SMCC, and the reaction mixture was passed over a Sephadex G-50 column to produce the purified streptavidin-NLSAlexa conjugate. The Streptavidin-conjugated oligonucleotide was prepared in a similar way. The oligonucleotide used for these studies was a thiol-modified, fluorescein-labeled oligonucleotide containing immunostimulatory CpG elements (18) . After reduction of CpG ODN by DTT, the free sulfhydryl group was reacted with streptavidin-SMCC, and the resulting streptavidin conjugate was purified by Sephadex G-50 column chromatography.
Research Report
The streptavidin-NLS-labeled plasmid was prepared by adding the purified streptavidin-NLS to biotin-PNAlabeled plasmid, and the product was analyzed by agarose gel electrophoresis. The results in Figure 4A show that the fluorescent-NLS-streptavidin conjugate was bound to the biotin-labeled plasmid ( Figure 4A, lane 3) . The conjugate did not bind to the same plasmid labeled with PNA-SMCC ( Figure 4A , lane 4) showing that streptavidin binding to the plasmid was dependent on the presence of biotin-PNA on the plasmid, as expected.
Streptavidin-CpG ODN-labeled plasmid was prepared by adding the purified streptavidin-CpG ODN conjugate to biotin-PNA-labeled plasmid. The labeled DNA was similarly analyzed by agarose gel electrophoresis, and the results are shown in Figure 4B . The fluoresceinCpG ODN-streptavidin conjugate bound to biotin-labeled plasmid ( Figure 4B , lane 3) but not to SMCC-PNA-labeled plasmid ( Figure 4B, lane 4) . These results show that sulfhydryl-containing peptides and oligonucleotides can be coupled to streptavidin maleimide, and the resulting streptavidin conjugates bind to biotin-PNA-labeled plasmid.
Direct Use of PNA-SMCC to Link Ligands to Plasmid DNA
Another PDGC approach is illustrated in Figure 5 . Here, the maleimide moiety is conjugated directly to the PNA. The NHS ester end of the SMCC was first reacted with the 5 ′ primary amine of the PNA clamp to form a stable amide bond. Then, the maleimide-PNA conjugate was hybridized to its binding site on the plasmid. The results in Figure 5 , A and B, show that peptides or oligonucleotides containing a free sulfhydryl group can react directly with the maleimide moiety on the PNA-DNA hybrid. Plasmid DNA containing the PNA binding site was incubated with SMCC-PNA to allow hybridization and the mixture was ethanol precipitated to remove free PNA.
The NLS peptide containing a terminal cysteine residue was reduced and mixed with maleimide-PNA labeled plasmid. The mixture was purified by ethanol precipitation and examined by The plasmid/PNA-biotin hybrid is used to capture streptavidin. A heterobifunctional cross-linker can be used to covalently attach peptides, proteins, oligonucleotides or other types of ligand to streptavidin. When these streptavidin-ligand conjugates are added directly to biotin-PNA-labeled plasmid, they will bind irreversibly to the biotin-PNA plasmid hybrid.
agarose gel electrophoresis. The results in Figure 5A show that the plasmid containing reactive maleimide became labeled with the NLS (lane 2), but a plasmid containing biotin-PNA was not labeled (lane 3). These results demonstrate that labeling is dependent on the reaction between the reduced sulfhydryl group and maleimide moiety on the PNA. DNA/PNA-fluorescein was used as a control to show where the DNA migrated into the gel ( Figure 5A 
DISCUSSION
In a previous report, we described how fluorophore-conjugated PNAs could be used to produce fluorescently labeled plasmid by hybridizing the fluorescent PNA to a binding site cloned into the plasmid (16, 22) . This labeling method does not change the supercoiled conformation of the plasmid or its ability to be efficiently transcribed. We now show how this method can be used to couple peptides and oligonucleotides onto DNA and describe two approaches. The first approach involves making peptide-or oligonucleotide-streptavidin conjugates and then binding them to biotin-PNA-labeled plasmid. The streptavidin conjugates are prepared by reacting streptavidin-maleimide with ligands containing a free thiol residue. The second approach uses a maleimide-PNA conjugate, which can be hybridized to the plasmid and then reacted with a ligand containing a free thiol residue.
The PDGC technology that is described in this report will give investigators a means of carrying out medicinal chemistry with genes. Medicinal chemistry is a classical approach to drug discovery that is commonly used for small molecule drug development to make systematic chemical modifications of biologically active agents to improve their bioavailability and efficacy. Being able to carry out a medicinal chemistry approach to improve the bioavailability and efficacy of DNA is presently lacking because the methods that have been used to directly modify DNA either reduce or destroy its ability to be transcribed. Since PNA binding is sequence dependent, it can be designed to bind to a region of the plasmid that does not interfere with the promoter/enhancer or the coding region and so it enables chemistry to be carried out on the PNA/DNA hybrid without destroying the activity of the gene.
Binding of peptides or proteins to plasmids may influence their delivery and expression in ways that are illustrated in Figure 6 . A ligand (PNA-lig) that binds to a cell surface receptor can be attached to a plasmid, directing the plasmid specifically to the targeted cell. An endosomolytic peptide (PNA-lyt) can be attached to the DNA so that endocytosed plasmid can more efficiently escape the endosomal compartment. An NLS peptide (PNA-nuc) attached to the plasmid may enable it to pass more efficiently across the nuclear membrane of nondividing cells. By using different PNA binding sites together with their complementary PNA clamps, different ligands can be attached to the same plasmid at the same time. This strategy will eventually enable the assembly of DNA containing a targeting ligand, an endosomolytic element and an NLS all attached to the same plasmid. Naked DNA is already active in many in vivo settings; the addition of one or more of these elements might be expected to improve its in vivo delivery and expression.
In addition to improving plasmid delivery, PDGC has other potential applications that are not directly related to gene therapy. With respect to DNA vaccines, we show that oligonucleotides containing immunostimulatory sequences can be attached to plasmid. Oligonucleotides of this kind may be used to improve the immunogenicity and vaccine potency of DNA vaccines (18) . In the virology field, it will be possible to test for the activity of individual viral proteins by binding them to plasmids; transfecting plasmids containing viral proteins into cells may influence their delivery or expression. In the area of signal transduction, a transcription activation peptide (PNAscript in Figure 6 ) may allow the plasmid to be transcribed without requiring intracellular transcription factors. In this way, transcription factors or peptides may be directly studied for their ability to modulate transcription.
Two approaches are described here for linking peptides and oligonucleotides to plasmids. In the first case, the ligands are bound to the plasmid through a streptavidin bridge, and the ligands are displayed in the context of a protein environment. In the second case, the ligands are coupled directly to the PNA clamp and are presented in close apposition to the DNA. The microenvironments in the immediate vicinity of peptides that are displayed in these two contexts are quite different, and so their biological activities may also differ. For example, a positively charged nuclear localization peptide that is coupled directly to DNA through the PNA clamp might be expected to interact strongly with the negatively charged DNA phosphodiester backbone, which makes it inaccessible to the proteins of the nuclear pore complex. But nuclear localization signals bound directly to proteins, such as BSA and streptavidin, have already been shown to retain their ability to deliver the conjugated protein into the nucleus of cells (1, 14) . Thus, when examining the effect of a ligand on the delivery or expression of a plasmid, it will be important to compare the activities of the ligand as displayed in both the protein (streptavidin) environment and in closer apposition to the DNA without the streptavidin bridge. The PDGC technology has been designed to be extremely versatile. The copy number of a ligand bound to the plasmid can be varied according to the need, simply by cloning into the plasmid the desired number of PNA binding sites. In addition, we have also shown that different PNA binding sites can be used to incorporate different ligands into the same plasmid. For example, a nuclear localization peptide can be added to one of the sites and a fluorophore to the second site. In this way, the changes in the intracellular biodistribution of the plasmid mediated by the NLS can be conveniently monitored. A plasmid containing three different PNA binding sites could be constructed with a ligand for a cell surface receptor, an endosomolytic peptide and an NLS all on the same plasmid. Therefore, the application of this technology will provide a versatile tool to help elucidate biological mechanisms in cell biology and physiology and ultimately, to help improve the performance of synthetic gene delivery systems for applications in gene therapy.
